The growth in the historic period can be attributed to limitations of conventional gout therapies, increasing prevalence of chronic gout, clinical success of pegloticase, rising comorbid conditions, expansion of specialty rheumatology practices.
The growth in the forecast period can be attributed to growing refractory gout patient pool, increased referral to specialty clinics, expansion of infusion services, supportive reimbursement for biologics, continued unmet need in severe gout. Major trends in the forecast period include growth in biologic therapies for refractory gout, focus on uric acid lowering enzyme treatments, specialty management of chronic gout patients, expansion of infusion based rheumatology care, rising use in severe and treatment resistant cases.
The increasing incidence of gout disease is expected to propel the growth of the Krystexxa market going forward. Gout disease refers to a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to inflammation, pain, and swelling. The increased incidence of gout disease is attributed to factors such as poor dietary habits, obesity, aging, certain medications, genetics, chronic kidney disease, a sedentary lifestyle, and comorbid conditions like high blood pressure and diabetes. Krystexxa (pegloticase) helps gout patients by lowering uric acid levels in the blood, specifically targeting chronic gout that is resistant to conventional treatments, thereby reducing the frequency and severity of gout flare-ups and providing relief from the painful symptoms associated with this condition. For instance, in June 2024, according to Rheumatology and Therapy, a US-based international peer-reviewed medical journal, the prevalence of comorbid gout and chronic kidney disease in the United States was projected to increase from 7.9 million in 2023 to 8.6 million in 2027, then to 9.2 million in 2031, and reaching 9.6 million in 2035, representing a 29% increase from 2023 to 2035. Therefore, the increasing incidence of gout disease is driving the krystexxa market.
Key trend in the krystexxa market is focusing on advancement of immunomodulatory strategies such as rheumatology research dissemination initiative to enhance clinical evidence visibility, support informed therapeutic decision-making, and strengthen stakeholder understanding of emerging advancements in inflammatory and autoimmune disease management. Rheumatology research dissemination initiative refers to a structured scientific communication effort aimed at presenting, sharing, and promoting new clinical findings, therapeutic data, and investigational insights within the field of rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, presented innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, highlighting new clinical data related to Krystexxa (pegloticase). The research showcased expanded evidence on treatment response patterns, patient-reported outcomes, and immunologic behavior when using advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, continues to demonstrate unique clinical benefits for adults with uncontrolled chronic gout by leveraging precision immune modulation to improve efficacy and manage anti-drug antibody formation. These new insights presented by Amgen reinforce Krystexxa’s role as a leading biologic option for patients with severe gout who have not responded adequately to conventional therapies.
In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. With the acquisition of Horizon Therapeutics, Amgen Inc. aims to significantly strengthen its position in the rare disease and inflammation market. Horizon Therapeutics Plc is an Ireland-based biopharmaceutical company that specializes in providing Krystexxa.
Major companies operating in the krystexxa market are Amgen Inc.
North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the krystexxa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the krystexxa market by increasing costs associated with biologic manufacturing, vial components, and international logistics. Specialty clinics and hospitals in import dependent regions experience higher procurement expenses. These pressures may affect treatment affordability for refractory gout patients. However, tariffs are encouraging localized biologics production and supply diversification. This supports long term access to advanced gout therapies.
The krystexxa market research report is one of a series of new reports that provides krystexxa market statistics, including krystexxa industry global market size, regional shares, competitors with a krystexxa market share, detailed krystexxa market segments, market trends and opportunities, and any further data you may need to thrive in the krystexxa industry. This krystexxa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Krystexxa (pegloticase) is a medication used to treat chronic gout in patients who are refractory to conventional therapies. It is an intravenous infusion that works by breaking down uric acid, thereby reducing uric acid levels in the body, which can help prevent gout attacks and related complications.
The main formulations in the krystexxa market are injectable formulation (lyophilized powder) and ready-to-use solutions. Krystexxa's injectable formulation, which is a lyophilized powder, refers to a freeze-dried form of the drug that is reconstituted with a diluent before administration. The various indications include treatment of chronic gout, management of hyperuricemia in gout patients, and treatment of refractory gout, and several patient demographics including adult patients, elderly patients and patients with comorbid conditions. Distribution channels for these treatments include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, rheumatology practices, and home healthcare providers.
The krystexxa market consists of sales of pegloticase and infusion kits sales. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to growing refractory gout patient pool, increased referral to specialty clinics, expansion of infusion services, supportive reimbursement for biologics, continued unmet need in severe gout. Major trends in the forecast period include growth in biologic therapies for refractory gout, focus on uric acid lowering enzyme treatments, specialty management of chronic gout patients, expansion of infusion based rheumatology care, rising use in severe and treatment resistant cases.
The increasing incidence of gout disease is expected to propel the growth of the Krystexxa market going forward. Gout disease refers to a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to inflammation, pain, and swelling. The increased incidence of gout disease is attributed to factors such as poor dietary habits, obesity, aging, certain medications, genetics, chronic kidney disease, a sedentary lifestyle, and comorbid conditions like high blood pressure and diabetes. Krystexxa (pegloticase) helps gout patients by lowering uric acid levels in the blood, specifically targeting chronic gout that is resistant to conventional treatments, thereby reducing the frequency and severity of gout flare-ups and providing relief from the painful symptoms associated with this condition. For instance, in June 2024, according to Rheumatology and Therapy, a US-based international peer-reviewed medical journal, the prevalence of comorbid gout and chronic kidney disease in the United States was projected to increase from 7.9 million in 2023 to 8.6 million in 2027, then to 9.2 million in 2031, and reaching 9.6 million in 2035, representing a 29% increase from 2023 to 2035. Therefore, the increasing incidence of gout disease is driving the krystexxa market.
Key trend in the krystexxa market is focusing on advancement of immunomodulatory strategies such as rheumatology research dissemination initiative to enhance clinical evidence visibility, support informed therapeutic decision-making, and strengthen stakeholder understanding of emerging advancements in inflammatory and autoimmune disease management. Rheumatology research dissemination initiative refers to a structured scientific communication effort aimed at presenting, sharing, and promoting new clinical findings, therapeutic data, and investigational insights within the field of rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, presented innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, highlighting new clinical data related to Krystexxa (pegloticase). The research showcased expanded evidence on treatment response patterns, patient-reported outcomes, and immunologic behavior when using advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, continues to demonstrate unique clinical benefits for adults with uncontrolled chronic gout by leveraging precision immune modulation to improve efficacy and manage anti-drug antibody formation. These new insights presented by Amgen reinforce Krystexxa’s role as a leading biologic option for patients with severe gout who have not responded adequately to conventional therapies.
In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. With the acquisition of Horizon Therapeutics, Amgen Inc. aims to significantly strengthen its position in the rare disease and inflammation market. Horizon Therapeutics Plc is an Ireland-based biopharmaceutical company that specializes in providing Krystexxa.
Major companies operating in the krystexxa market are Amgen Inc.
North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the krystexxa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the krystexxa market by increasing costs associated with biologic manufacturing, vial components, and international logistics. Specialty clinics and hospitals in import dependent regions experience higher procurement expenses. These pressures may affect treatment affordability for refractory gout patients. However, tariffs are encouraging localized biologics production and supply diversification. This supports long term access to advanced gout therapies.
The krystexxa market research report is one of a series of new reports that provides krystexxa market statistics, including krystexxa industry global market size, regional shares, competitors with a krystexxa market share, detailed krystexxa market segments, market trends and opportunities, and any further data you may need to thrive in the krystexxa industry. This krystexxa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Krystexxa (pegloticase) is a medication used to treat chronic gout in patients who are refractory to conventional therapies. It is an intravenous infusion that works by breaking down uric acid, thereby reducing uric acid levels in the body, which can help prevent gout attacks and related complications.
The main formulations in the krystexxa market are injectable formulation (lyophilized powder) and ready-to-use solutions. Krystexxa's injectable formulation, which is a lyophilized powder, refers to a freeze-dried form of the drug that is reconstituted with a diluent before administration. The various indications include treatment of chronic gout, management of hyperuricemia in gout patients, and treatment of refractory gout, and several patient demographics including adult patients, elderly patients and patients with comorbid conditions. Distribution channels for these treatments include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, rheumatology practices, and home healthcare providers.
The krystexxa market consists of sales of pegloticase and infusion kits sales. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Krystexxa Market Characteristics
3. Krystexxa Market Supply Chain Analysis
4. Global Krystexxa Market Trends and Strategies
5. Krystexxa Market Analysis of End Use Industries
7. Global Krystexxa Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Krystexxa Total Addressable Market (TAM) Analysis for the Market
9. Krystexxa Market Segmentation
10. Krystexxa Market Regional and Country Analysis
11. Asia-Pacific Krystexxa Market
12. China Krystexxa Market
13. India Krystexxa Market
14. Japan Krystexxa Market
15. Australia Krystexxa Market
16. South Korea Krystexxa Market
17. Western Europe Krystexxa Market
18. UK Krystexxa Market
19. Germany Krystexxa Market
20. France Krystexxa Market
21. Eastern Europe Krystexxa Market
22. North America Krystexxa Market
23. USA Krystexxa Market
24. Canada Krystexxa Market
25. South America Krystexxa Market
26. Middle East Krystexxa Market
27. Africa Krystexxa Market
29. Krystexxa Market Competitive Landscape and Company Profiles
32. Krystexxa Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Krystexxa Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses krystexxa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for krystexxa? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The krystexxa market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Formulation: Injectable Formulation (Lyophilized Powder); Ready-To-Use Solutions2) By Indication: Treatment Of Chronic Gout; Management Of Hyperuricemia In Gout Patients; Treatment Of Refractory Gout
3) By Patient Demographics: Adult Patients; Elderly Patients; Patients With Comorbid Conditions
4) By Distribution Channel: Direct Sales; Wholesalers And Distributors; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Specialty Clinics; Rheumatology Practices; Home Healthcare Providers
Companies Mentioned: Amgen Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Krystexxa market report include:- Amgen Inc.
